Ramiprilat (Standard)
Based on 1 Customer Validation
Alvimopan (dihydrate) (Standard) is the analytical standard of Alvimopan (dihydrate). This product is intended for research and analytical applications. Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus.
For research use only. We do not sell to patients.
- Purity: 96.61%
- CAS No.: 87269-97-4
- Formula: C21H28N2O5
- Molecular Weight:388.46
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 87269-97-4
-
Appearance Solid
-
Molecular Weight 388.46
-
Formula C21H28N2O5
-
Color White to off-white
-
SMILES
O=C([C@@H]1C[C@@](CCC2)([H])[C@@]2([H])N1C([C@@H](N[C@H](C(O)=O)CCC3=CC=CC=C3)C)=O)O
-
Synonyms
HOE 498 diacid (Standard); Ramipril diacid (Standard)
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ramiprilat (HOE 498 diacid), an active metabolite of Ramipril, is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with a Ki value of 7 pM. Ramiprilat can be used for high blood pressure and heart failure research[1]. [Content Brief]
[2]. Wiemer G, et al. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 1991 Oct;18(4):558-63. [Content Brief]
[3]. Wall TM, et al. Ramiprilat attenuates hypoxia/reoxygenation injury to cardiac myocytes via a bradykinin-dependent mechanism. Eur J Pharmacol. 1996 Jun 13;306(1-3):165-74. [Content Brief]
[4]. Serrano-Rodríguez JM, et al. Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses. Vet J. 2016 Feb;208:38-43. [Content Brief]
[5]. Cachofeiro V, et al. Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension. 1992 Feb;19(2):138-45. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)